Sage Therapeutics, Inc. (SAGE) Stock

SAGE logo

Sage Therapeutics, Inc.

SAGE
Healthcare

Company profile

Sage Therapeutics reported revenue of $41.24 million for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was $31.66 million, up 265.8% from a year before. In Q2 2025 it reported a net loss of $49.65 million, against a net loss of $102.85 million a year earlier. Our analysis of its filings shows revenue growing from $7.69 million in fiscal year 2022 to $41.24 million in fiscal year 2024, 131.6% a year on average.

What stands out

  • Revenue fell 52.3% in fiscal year 2024, from $86.46 million in fiscal year 2023, after a rise of 1024.8% the year before.
  • It reported a net loss in each of its last 4 fiscal years, after a profit of $606.07 million in fiscal year 2020; the loss narrowed from $541.49 million in fiscal year 2023 to $400.67 million in fiscal year 2024.
  • It spent $225.90 million on research and development in fiscal year 2024, 5.5 times its revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

How much revenue does Sage Therapeutics make?

Sage Therapeutics reported $41.24 million in revenue for fiscal year 2024, down 52.3% from $86.46 million in fiscal year 2023. In Q2 2025 revenue was $31.66 million.

What companies are similar to Sage Therapeutics?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Kalbe Farma Tbk. (KLBF.JK), Alteogen Inc. (196170.KQ), Chugai Pharmaceutical Co., Ltd. (4519.T), DHG Pharmaceutical Joint Stock Company (DHG.VN).

How has Sage Therapeutics' revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, $1.11 billion; FY2021, $6.31 million; FY2022, $7.69 million; FY2023, $86.46 million; FY2024, $41.24 million.

Has Sage Therapeutics made a profit in recent years?

Net income by fiscal year: FY2020, $606.07 million; FY2021, a loss of $457.89 million; FY2022, a loss of $532.78 million; FY2023, a loss of $541.49 million; FY2024, a loss of $400.67 million. It reported a net loss in 4 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Founded2010
IPO DateJul 18, 2014
IPO StatusPublic
FoundersDouglas Covey, Steven Paul
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Sage Therapeutics, Inc. (SAGE)”, data as of Jun 30, 2025, https://dataporium.tech/stocks/SAGE

LinkedInLinkedInXXYouTubeYouTube